221 related articles for article (PubMed ID: 31018250)
1. NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.
Sottile R; Tannazi M; Johansson MH; Cristiani CM; Calabró L; Ventura V; Cutaia O; Chiarucci C; Covre A; Garofalo C; Pontén V; Tallerico R; Frumento P; Micke P; Maio M; Kärre K; Carbone E
Int J Cancer; 2019 Oct; 145(8):2238-2248. PubMed ID: 31018250
[TBL] [Abstract][Full Text] [Related]
2. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
3. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
[TBL] [Abstract][Full Text] [Related]
4. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
5. Tremelimumab for the treatment of malignant mesothelioma.
Guazzelli A; Hussain M; Krstic-Demonacos M; Mutti L
Expert Opin Biol Ther; 2015; 15(12):1819-29. PubMed ID: 26560442
[TBL] [Abstract][Full Text] [Related]
6. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.
Lima M; Almeida J; Montero AG; Teixeira Mdos A; Queirós ML; Santos AH; Balanzategui A; Estevinho A; Algueró Mdel C; Barcena P; Fonseca S; Amorim ML; Cabeda JM; Pinho L; Gonzalez M; San Miguel J; Justiça B; Orfão A
Am J Pathol; 2004 Oct; 165(4):1117-27. PubMed ID: 15466379
[TBL] [Abstract][Full Text] [Related]
7. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
[TBL] [Abstract][Full Text] [Related]
9. The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.
Chieregato K; Zanon C; Castegnaro S; Bernardi M; Amati E; Sella S; Rodeghiero F; Astori G
Blood Transfus; 2017 Jan; 15(1):93-100. PubMed ID: 27136441
[TBL] [Abstract][Full Text] [Related]
10. Low-frequency, exhausted immune status of CD56
Pan Z; Zhao R; Shen Y; Liu K; Xue W; Liang C; Peng M; Hu P; Chen M; Xu H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108369. PubMed ID: 34844872
[TBL] [Abstract][Full Text] [Related]
11. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
12. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L; Ceresoli GL; di Pietro A; Cutaia O; Morra A; Ibrahim R; Maio M
Cancer Immunol Immunother; 2015 Jan; 64(1):105-12. PubMed ID: 25233793
[TBL] [Abstract][Full Text] [Related]
13. Human peripheral blood DNAM-1
Stannard KA; Lemoine S; Waterhouse NJ; Vari F; Chatenoud L; Gandhi MK; Martinet L; Smyth MJ; Guillerey C
Blood Adv; 2019 Jun; 3(11):1681-1694. PubMed ID: 31167820
[TBL] [Abstract][Full Text] [Related]
14. Selective downregulation of natural killer activating receptors on NK cells and upregulation of PD-1 expression on T cells in children with severe and/or recurrent Herpes simplex virus infections.
Lenart M; Kluczewska A; Szaflarska A; Rutkowska-Zapała M; Wąsik M; Ziemiańska-Pięta A; Kobylarz K; Pituch-Noworolska A; Siedlar M
Immunobiology; 2021 May; 226(3):152097. PubMed ID: 34015527
[TBL] [Abstract][Full Text] [Related]
15. Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.
Chalan P; Bijzet J; Kroesen BJ; Boots AM; Brouwer E
J Rheumatol; 2016 Jun; 43(6):1008-16. PubMed ID: 27036380
[TBL] [Abstract][Full Text] [Related]
16. The biology of human natural killer-cell subsets.
Cooper MA; Fehniger TA; Caligiuri MA
Trends Immunol; 2001 Nov; 22(11):633-40. PubMed ID: 11698225
[TBL] [Abstract][Full Text] [Related]
17. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
18. Impaired circulating CD56
Jiang Y; Chen Y; Chen L; Yao W; Guan J; Liu X; Wei X; Lin X
Hum Immunol; 2020 Jan; 81(1):32-40. PubMed ID: 31735440
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
20. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset.
Mace EM; Hsu AP; Monaco-Shawver L; Makedonas G; Rosen JB; Dropulic L; Cohen JI; Frenkel EP; Bagwell JC; Sullivan JL; Biron CA; Spalding C; Zerbe CS; Uzel G; Holland SM; Orange JS
Blood; 2013 Apr; 121(14):2669-77. PubMed ID: 23365458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
